SEARCH

SEARCH BY CITATION

References

  • 1
    Strader DB, Wright T, Thomas DL, Seeff LB. AASLD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 114771.
  • 2
    Manns MP, McHutchison JG, Gordon SC, et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 95865.
  • 3
    Fried MW, Shiffman ML, Reddy KR, et al. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 4
    Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140: 34655.
  • 5
    McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10619.
  • 6
    Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44.
  • 7
    Zapater P, Lasso De La Vega MC, Horga JF, et al. Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. Aliment Pharmacol Ther 2004; 20: 18.
  • 8
    Laffi G, LaVilla G, Pinzani M, Marra F, Gentilini P. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997; 17: 53048.
  • 9
    Hourigan LF, MacDonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C, correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 12159.
  • 10
    Adinoffi LE, Cambardella M, Adreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 135864.
  • 11
    Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 7585.
  • 12
    Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 48490.
  • 13
    Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, Layden TJ. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C. Dig Dis Sci 1997; 42: 17885.
  • 14
    Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RL Jr. Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat 2000; 7: 2117.
  • 15
    Cotler SJ, Patil R, McNutt RA, et al. Patients’ values for health states associated with hepatitis C and physicians’ estimates of those values. Am J Gastroenterol 2001; 96: 27306.
    Direct Link:
  • 16
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 20912.
  • 17
    Singh N, Gayowski T, Wagener MM, Marino IR. Vulnerability to psychological distress and depression in patients with end-stage liver disease due to hepatitis C virus. Clin Transplant 1997; 11: 40611.
  • 18
    Golding CO, Connell P, Murray FE. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol 2001; 13: 50711.
  • 19
    Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998; 93: 7859.
    Direct Link:
  • 20
    Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 86776.
  • 21
    Otsubo T, Miyaoka H, Kamijima K, et al. Depression during interferon therapy in chronic hepatitis – a prospective study. Seishin Shinkeigaku Zasshi 1997; 99: 10127.
  • 22
    Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999; 354: 1312.
  • 23
    Miyaoka H, Otsubo T, Kamijima K, Ishii M, Nuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156: 1120.
  • 24
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Intervention Therapy Group. N Engl J Med 1998; 339: 148592.
  • 25
    Davis GL, Esteban-Muir R, Rustgi V, et al. Interferon alfa-2a alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 14939.
  • 26
    Goldman LS. Successful treatment of interferon alfa-induced mood disorder with nortriptyline. Psychosomatics 1994; 35: 4123.
  • 27
    Schramm TM, Lawford BR, Macdonald GA, Cooksley WG. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173: 35961.
  • 28
    Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88: 7601.
  • 29
    Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40: 5102.
  • 30
    Maddock C, Baita A, Orru MG, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004; 18: 416.
  • 31
    Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alpha. N Engl J Med 2001; 344: 9616.
  • 32
    Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 9427.
  • 33
    Pockros PJ, Carithers R, Desmond P, et al. Efficacy and safety of a 2-dose regimens of peg interferon alfa-2a compared with interferon alfa-2a in chronic hepatitis C: a multicenter randomized controlled trial. Am J Gastroenterol 2004; 99: 1298305.
    Direct Link:
  • 34
    Kontorinis N, Agarwal K, Dieterich DT. Current status of the use of growth factors and other adjuvant medications in patients receiving peginterferon and ribavirin. Rev Gastroenterol Disord 2004; 4(Suppl. 1): S3947.
  • 35
    Soza A, Everhart JE, Glramy MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 12739.
  • 36
    Ahmed F, Jacobson IM, Brown RS Jr, et al. Clinical significance of pegylated interferon induced neutropenia: results from the WIN-R trial. Gastroenterology 2003; 124: A-700.
  • 37
    Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 14249.
  • 38
    Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 2000; 96: 20939.
  • 39
    Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002; 97: 20405.
    Direct Link:
  • 40
    Marinos G, Rustgi VK. Safety of interferon/ribavirin therapy in patients with thrombocytopenia using recombinant human IL-11 (Abstract 639). Hepatology 2001; 34: 332A.
  • 41
    Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11: 847.
  • 42
    De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 9971004.
  • 43
    Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002; 123: 14151.
  • 44
    Tanaka N, Ishida F, Tanaka E. Ribavirin-induced pure red-cell aplasia during treatment of chronic hepatitis C. N Engl J Med 2004; 350: 12645.
  • 45
    PEG-IntronTM (recombinant peginterferon alfa-2b) package insert. Kenilworth, NJ: Schering Corporation, 2003.
  • 46
    Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 55565.
  • 47
    Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 101523.
  • 48
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peg interferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 64552.
  • 49
    Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 130211.
  • 50
    Azzam H, Ahmed F, Peterson B, et al. Delayed recovery of pegylated interferon and ribavirin induced anemia. Hepatology 2003; 38: 751A (abstract).
  • 51
    Younossi ZM, Ong JP, Collantes R, et al. Darbepoetin alfa for ribavirin-induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirin: a preliminary analysis. Gastroenterology 2004; 126: A666 (abstract).
  • 52
    Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 10029.
  • 53
    Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drugs 2002; 3: 6803.
  • 54
    Wu JZ, Walker H, Lau JY, Hong Z. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother 2003; 47: 42631.
  • 55
    Gish R, Arora S, Nelson D, et al. Safety and Efficacy of Viramidine in Combination with Pegylated Interferon Alfa-2a for Treatment of Hepatitis C in Therapy-naive Patients. Program and Abstracts of the 39th Annual Meeting of The European Association for the Study of the Liver Berlin, Germany, 2004 (abstract 479/762).